

**BERESKIN & PARR**BOX 401, 40 KING STREET WEST, TORONTO, CANADA M5H 3Y2
PHONE (416) 364-7311 • FAX (416) 361-1398 • WWW.BERESKINPARR.COM

DTOS rec'd PCT/PTO 30 OCT 2002

P#9

Please type a plus sign (+) inside this box → ☐Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/089,058	
	Filing Date	October 4, 2000	
	First Named Inventor	Curtis Braun	
	Group Art Unit	Unknown as of Yet	
	Examiner Name	Unknown as of Yet	
Total Number of Pages in This Submission	8	Attorney Docket Number	10447-22

RECEIVED
MAR 06 2003
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	* - in addition to the 4 pages being submitted, 143 references (patents and publications) are enclosed	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Micheline Gravelle, Registration No. 40,261
Signature	<i>M. Gravelle</i>
Date	October 29, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
Typed or printed name		<input type="text"/>	
Signature	<input type="text"/>	Date	<input type="text"/>

⊕ Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



October 29, 2002

Bereskin & Parr



Barristers and Solicitors/Patent and Trade Mark Agents
Practice Restricted to Intellectual Property Law

Micheline Gravelle B.Sc., M.Sc. (Immunology.)
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 10/089,058
Our Reference: 10447-22

The Commissioner of Patents
& Trademarks
Washington, D.C. 20231
U.S.A.

Dear Sir:

Re: FILING OF AN INFORMATION DISCLOSURE STATEMENT
United States Patent Application No. 10/089,058
Filing Date: October 4, 2000
Entitled: Improved Ricin-Like Toxins for Treatment of Cancer
Inventors: Curtis Braun, Admir Purac and Thor Borgford

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language and accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column. Applicant reserves the right to contest the applicability of any of these documents as prior art against the subject application.

please send your reply to:

Scotia Plaza, 40 King Street West, 40th Floor
Toronto, Ontario, Canada M5H 3Y2
416 364 7311 fax: 416 361 1398

Meadowvale Corporate Centre, 2000 Argentia Road
Plaza 4, Suite 430, Mississauga, Ontario, Canada L5N 1W1
905 812 3600 fax: 905 814 0031

www.bereskinparr.com

This Information Disclosure Statement is being filed within three months of the filing of the application or before the mailing date of a first Office Action on the merits; therefore, no fee is required.

If the Examiner has any questions concerning this Information Disclosure Statement, he is requested to contact the undersigned. If it is determined that this Information Disclosure Statement has been filed under the wrong rule, the Patent and Trademark Office is requested to consider this Information Disclosure Statement under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 02-2095.

If additional fees are required, please charge the fees to our Deposit Account No. 02 2095.

Respectfully submitted,

**Curtis Braun, Admir Purac
& Thor Borgford**

A handwritten signature in cursive script, appearing to read "M. Gravelle".

Micheline Gravelle
Registration No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario
Canada M5H 3Y2

(416) 364-7311



Form PTO-1449 (REV. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 10447-022		SERIAL NO.: 10/089,058	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANTS: Curtis Braun et al.		GROUP: RECEIVED TECH CENTER 1600/2300 MAR 06 2003	
				FILING DATE: October 4, 2000			
U.S. PATENT DOCUMENTS							
*EXA-MINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILED DATE IF APPROVED
		4,869,903	1989-09-25	Lifson et al.			
		5,101,025	1992-03-31	Piatak Jr. et al.			
		5,128,460	1992-07-07	Piatak Jr. et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	<u>TRANSLATION</u> YES NO
		EP 145,111	1992-01-15	Europe			
		EP 466,222	1985-06-19	Europe			
		WO89/04839	1989-06-01	PCT			
		WO94/18332	1994-08-18	PCT			
		WO97/41233	1997-11-06	PCT			
		WO98/49311	1998-11-05	PCT			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
	1.	Abad-Zapatero, C. et al., <i>Protein Sci.</i> 5:640-652 (1996)					
	2.	Allured, V.S. et al., <i>Proc. Natl. Acad. Sci. USA</i> 83:1320-1324 (1986)					
	3.	Bever Jr., C.T., Panitch, H.S., and Johnson, K.P. (1994) <i>Neurology</i> 44(4), 745-8.					
	4.	Blackman, M.J. et al. (<i>Mol. Biochem. Parasitol.</i> 62:103-114 (1995 or 1993?))					
	5.	Blaha, I. et al., <i>FEBS Lett.</i> 309:389-393 (1992)					
* EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Form PTO-1449 (REV. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 10447-022	SERIAL NO.: 10/089,058
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANTS: Curtis Braun et al.	
				FILING DATE: October 4, 2000	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
	6.	Blum, J.S. et al., <i>J. Biol. Chem.</i> 266: 22091-22095 (1991)			
	7.	Bonifacino, J.S., <i>Nature</i> 384: 405-406 (1996)			
	8.	Carvalho, K. et al., <i>Biochem. Biophys. Res. Comm.</i> 191:172-179 (1993)			
	9.	Chirgwin et al., <i>Biochemistry</i> 18, 5294-5299 (1979)			
	10.	Cohen, P., Graves, H.C., Peehl, D.M., Kamarei, M., Giudice, L.C., and Rosenfeld, R.G. (1992) <i>Journal of Clinical Endocrinology and Metabolism</i> 75(4), 1046-53.			
	11.	Collier, R.J. & Kandel, J., <i>J. Biol. Chem.</i> 246:1496-1503 (1971)			
	12.	Collier, R.J. et al., <i>J. Biol. Chem.</i> 257:5283-5285 (1982)			
	13.	Columblatti, M. et al., <i>J. Biol. Chem.</i> 261:3030-3035 (1986)			
	14.	Conover, C.A. and De Leon, D.D., <i>J. Biol. Chem.</i> 269(10), 7076-80 (1994)			
	15.	Cook, J.P. et al., <i>Bioconjugate Chem.</i> 4, 440-447 (1993)			
	16.	Cooper, J.A. and Bujard, H. (<i>Mol. Biochem. Parasitol.</i> 56:151-160 (1992)			
	17.	Cutfield, S.M. et al., <i>Biochemistry</i> 35:398-410 (1995)			
	18.	Demeure, M.J. et al., <i>World J. Surg.</i> 16:770-776 (1992)			
	19.	DiIannit, 1990, <i>J. Biol. Chem.</i> 285: 17345-17354 (1990)			
	20.	Emmanuel, F. et al., <i>Anal. Biochem.</i> 173: 134-141 (1988)			
	21.	Endo, Y. & Tsurugi, K. J., <i>Biol. Chem.</i> 262:8128 (1987)			
	22.	Fiani, M.L. et al., <i>Arch. Biochem. Biophys.</i> 307: 225-230 (1993)			
	23.	Funmatsu et al., <i>Jap. J. Med. Sci. Biol.</i> 23:264-267 (1970)			
	24.	Fusek, M. et al. (<i>FEBS Lett.</i> 327:108-112 (1993)			
	25.	Garred, O. et al. (<i>J. Biol. Chem.</i> 270:10817-10821 (1995)			
	26.	Gluzman, Y. (1975) <i>Cell</i> , 23, 175 - 182)			
	27.	Goldberg, D.E. et al. (<i>J. Exp. Med.</i> 173:961-969 (1991)			
	28.	Gray, G.L. et al., <i>Proc. Natl. Acad. Sci. USA</i> 81:2645-2649 (1984)			
	29.	Greenfield, L. et al., <i>Proc. Natl. Acad. Sci. USA</i> 80:6853-6857 (1983)			
	30.	Halling, K. et al. <i>Nucleic Acids Res.</i> 13:8019 (1985)			
	31.	Hansen, G., Schuster, A., Zubrod, C., and Wahn, V. (1995) <i>Respiration</i> 62(3), 117-24			
* EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

RECEIVED
MAR 06 2003
TECH CENTER 1800/2900



Form PTO-1449 (REV. 2-32)	DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 10447-22	SERIAL NO.: 10/089,058
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANTS: Curtis Braun et al.	
		FILING DATE: October 4, 2000	GROUP:
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)			
32.	Hirowatari, Y. et al., <i>Arch. Virol.</i> 133:349-356 (1993)		
33.	Hirowatari, Y. et al., <i>Anal. Biochem.</i> 225:113-120 (1995)		
34.	Holmberg, K. and Myer, R., <i>Scand. J. Infect. Dis.</i> 18:179-192 (1986)		
35.	Honn, K.V. et al. (<i>Biochem. Pharmacol.</i> 34:235-241 (1985)		
36.	Jewell, D.A. et al., <i>Biochemistry</i> 31:7862-7869 (1992)		
37.	Krane, S.M., <i>Ann. N.Y. Acad. Sci.</i> 732:1-10 (1994)		
38.	Lamb and Lord, <i>Eur. J. Biochem.</i> 14:265-270 (1985)		
39.	Leppla, S.H. et al. (Bacterial Protein Toxins <i>zbl.bakt.suppl.</i> 24:431-442 (1994)		
40.	Liu F. & Roizman, B. (<i>J. Virol.</i> 65:5149-5156 (1991)		
41.	Long, A.C. et al., <i>FEBS Lett.</i> 258:75-78 (1989)		
42.	Lord, J.M., <i>Eur. J. Biochem.</i> 146:411-416 (1985)		
43.	Lord, J.M., <i>Eur. J. Biochem.</i> 146:403-409 (1985)		
44.	Lord, J.M. et al., <i>FASAB Journal</i> 8:201-208 (1994)		
45.	Mackay, A.R. et al. <i>Lab. Invest.</i> 70:800-806 (1994)		
46.	May, M.J. et al. <i>Embo. Journal</i> , 8:301-308 at 302-303 (1989)		
47.	McKerrow, J.H. et al., <i>J. Biol. Chem.</i> 260:3703-3707 (1985)		
48.	McPherson, R.A. et al. (<i>Mol. Biochem. Parasitol.</i> 62:233-242 (1993)		
49.	Mikkelsen, T. et al. <i>J. Neurosurg.</i> 83:285-290 (1995)		
50.	Moore, D.H. et al. <i>Gynecol. Oncol.</i> 65:78-82 (1997)		
51.	Muller, H.L., Oh, Y., Gargosky, S.E., Lehrnbecher, T., Hintz, R.L., and Rosenfeld, R.G. (1993) <i>Journal of Clinical Endocrinology and Metabolism</i> 77(5), 1113-9.		
52.	Nakano et al. (1995) <i>J. of Neurosurgery</i> 83(2), 298-307		
53.	Nwagwu, M. et al. (<i>Exp. Parasitol.</i> 75:399-414 (1992)		
* EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED
MAR 08 2003
TECH CENTER 1600/2900



Form PTO-1449 (REV. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 10447-022	SERIAL NO.: 10/089,058
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANTS: Curtis Braun et al.	
		FILING DATE: October 4, 2000	GROUP:
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)			
54.	O'Dea, K.P. et al., <i>Mol. Biochem. Parasitol.</i> 72:111-119 (1995)		
55.	Ogata, M. et al., <i>J. Biol. Chem.</i> 267:25396-25401 (1992)		
56.	Olsnes, S. & Phil, A. in <i>Molecular action of toxins and viruses</i> (eds. Cohen, P. & vanHeyningen, S.) 51-105 Elsevier Biomedical Press, Amsterdam, 1982)		
57.	Olson et al., <i>AIDS Res. and Human Retroviruses</i> 7:1025-1030 (1991)		
58.	Panchal, R.G. et al., <i>Nature Biotechnology</i> 14:852-857 (1996)		
59.	Pastan et al., <i>Annals New York Academy of Sciences</i> 758:345-353 (1995)		
60.	Pastan, I. et al., <i>Annu. Rev. Biochem.</i> 61:331-354 (1992)		
61.	Peng, K-W, et al. <i>Human Gene Therapy</i> , 8:729-738 (1997)		
62.	Pettit, S.C. et al., <i>J. Biol. Chem.</i> 266:14539-14547 (1991)		
63.	Ray, T.L. and Payne, C.D. (<i>Infect. Immunol.</i> 58:508-514 (1990)		
64.	Remold, H.H. et al. (<i>Biochim. Biophys. Acta</i> 167:399-406 (1968)		
65.	Richardson, P.T. et al., <i>FEBS Lett.</i> 255:15-20 (1989)		
66.	Rosenthal, P.J. et al. (<i>J. Clin. Invest.</i> 91:1052-1056 (1993)		
67.	Ruchel, R. et al, <i>Zentralbl. Bakteriol. Mikrobiol Hyg. I Abt. Orig. A.</i> 255:537-548 (1983)		
68.	Rutenber, E. et al. <i>Proteins</i> 10:240-250 (1991)		
69.	Sandvig, K. et al., <i>Biochem. Soc. Trans.</i> 21:707-711 (1993)		
70.	Sandvig, K. & van Deurs, B., <i>FEBS Lett.</i> 346: 99-102 (1994)		
71.	Scarborough, P.E. et al., <i>Protein Sci.</i> 2:264-276 (1993)		
72.	Schreiber, B, et al., <i>Diagn. Microbiol. Infect. Dis.</i> 3:1-5 (1985)		
73.	Schwartz, M.K., <i>Clin. Chim. Acta</i> 237:67-78 (1995)		
74.	Shi, Y.E. et al., <i>Cancer Res.</i> 53:1409-1415 (1993)		
75.	Simmons et al., <i>Biol. Chem.</i> 261:7912 (1986)		
76.	Sloane, B.F. et al. (<i>Proc. Natl. Acad. Sci. USA</i> 83:2483-2487 (1986)		
* EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED
MAR 6 2003
TECH CENTER 1600/2900



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 10447-022	SERIAL NO.: 10/089,058
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANTS: Curtis Braun et al.	
		FILING DATE: October 4, 2000	GROUP:
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)			
77.	Spiess, E. et al., <i>J. Histochem. Cytochem.</i> 42:917-929 (1994)		
78.	Spooner et al., <i>Mol. Immunol.</i> 31:117-125, (1994)		
79.	Thompson, E.W. et al., <i>Breast Cancer Res. Treatment</i> 31:357-370 (1994)		
80.	Vasil, M.L. et al., <i>Infect. Immunol.</i> 16:353-361 (1977)		
81.	Vitetta et al., <i>Science</i> 238:1098-1104(1987)		
82.	Vitetta & Thorpe, <i>Seminars in Cell Biology</i> 2:47-58 (1991)		
83.	Vitetta et al., <i>Immunology Today</i> 14:252-259 (1993)		
84.	Weidner, J.R. et al. (<i>Arch. Biochem. Biophys.</i> 286:402-408 (1991)		
85.	Welch, A.R. et al. (<i>Arch. Biochem. Biophys.</i> 324:59-64 (1995)		
86.	Welch, A.R. (<i>Proc. Natl. Acad. Sci. USA</i> 88:10792-10796 (1991)		
87.	Wellner, R.B. et al. <i>J. Toxicol. Toxin Reviews</i> , 14(4), 483-522 (1995)		
88.	Westby et al., <i>Bioconjugate Chem.</i> 3:377-382 (1992)		
89.	Weston et al., <i>Mol. Biol.</i> 244:410-422 (1994)		
90.	Wiertz, E.J. et al., <i>Nature</i> 384: 432-438 (1996)		
91.	Woessner, J.F., <i>Ann. N.Y. Acad. Sci.</i> 732:11-21 (1994)		
92.	Young, T.N. et al. <i>Gynecol. Oncol.</i> 62:89-99 (1996)		
93.			
94.			
95.			
96.			
97.			
98.			
99.			
100.			
101.			
102.			
* EXAMINER: Initial if citation considered, whether or not citation is in accordance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED
MAR 06 2003
TECH CENTER 1600/2900